- Home
- CVKD vs ABP Comparison
CVKD vs ABP Comparison
Compare CVKD & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVKD | ABP |
|---|---|---|
| Founded | 2022 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7M | 12.5M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | CVKD | ABP |
|---|---|---|
| Price | $6.89 | $4.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | ★ 85.1K | 18.2K |
| Earning Date | 11-10-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.00 |
| 52 Week Low | $6.42 | $3.78 |
| 52 Week High | $22.90 | $60.15 |
Technical Indicators
Market Signals| Indicator | CVKD | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 35.29 | 35.01 |
| Support Level | $6.42 | $3.78 |
| Resistance Level | $7.62 | $5.08 |
| Average True Range (ATR) | 0.88 | 0.41 |
| MACD | -0.13 | -0.22 |
| Stochastic Oscillator | 7.65 | 14.23 |
Price Performance
Historical ComparisonAbout CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About ABP Abpro Holdings Inc
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.